GLUT-1 expression and response to chemoradiotherapy in rectal cancer.

Hdl Handle:
http://hdl.handle.net/10147/127502
Title:
GLUT-1 expression and response to chemoradiotherapy in rectal cancer.
Authors:
Brophy, Sarah; Sheehan, Katherine M; McNamara, Deborah A; Deasy, Joseph; Bouchier-Hayes, David J; Kay, Elaine W
Affiliation:
Department of Surgery, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland. sbrophy@rcsi.ie
Citation:
GLUT-1 expression and response to chemoradiotherapy in rectal cancer. 2009, 125 (12):2778-82 Int. J. Cancer
Journal:
International journal of cancer. Journal international du cancer
Issue Date:
15-Dec-2009
URI:
http://hdl.handle.net/10147/127502
DOI:
10.1002/ijc.24693
PubMed ID:
19569052
Abstract:
Preoperative chemoradiotherapy is used in locally advanced rectal cancer to reduce local recurrence and improve operability, however a proportion of tumors do not undergo significant regression. Identification of predictive markers of response to chemoradiotherapy would improve patient selection and may allow response modification by targeting of specific pathways. The aim of this study was to determine whether expression of glucose transporter-1 (GLUT-1) and p53 in pretreatment rectal cancer biopsies was predictive of tumor response to chemoradiotherapy. Immunohistochemical staining for GLUT-1 and p53 was performed on 69 pretreatment biopsies and compared to tumor response in the resected specimen as determined by the tumor regression grade (TRG) scoring system. GLUT-1 expression was significantly associated with reduced response to chemoradiotherapy and increasing GLUT expression correlated with poorer response (p=0.02). GLUT-1 negative tumors had a 70% probability of good response (TRG3/4) compared to a 31% probability of good response in GLUT-1 positive tumors. GLUT-1 may be a useful predictive marker of response to chemoradiotherapy in rectal cancer.
Item Type:
Article
Language:
en
MeSH:
Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Glucose Transporter Type 1; Humans; Immunoenzyme Techniques; Male; Middle Aged; Preoperative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Treatment Outcome; Tumor Markers, Biological; Tumor Suppressor Protein p53
ISSN:
1097-0215

Full metadata record

DC FieldValue Language
dc.contributor.authorBrophy, Sarahen
dc.contributor.authorSheehan, Katherine Men
dc.contributor.authorMcNamara, Deborah Aen
dc.contributor.authorDeasy, Josephen
dc.contributor.authorBouchier-Hayes, David Jen
dc.contributor.authorKay, Elaine Wen
dc.date.accessioned2011-04-06T14:46:35Z-
dc.date.available2011-04-06T14:46:35Z-
dc.date.issued2009-12-15-
dc.identifier.citationGLUT-1 expression and response to chemoradiotherapy in rectal cancer. 2009, 125 (12):2778-82 Int. J. Canceren
dc.identifier.issn1097-0215-
dc.identifier.pmid19569052-
dc.identifier.doi10.1002/ijc.24693-
dc.identifier.urihttp://hdl.handle.net/10147/127502-
dc.description.abstractPreoperative chemoradiotherapy is used in locally advanced rectal cancer to reduce local recurrence and improve operability, however a proportion of tumors do not undergo significant regression. Identification of predictive markers of response to chemoradiotherapy would improve patient selection and may allow response modification by targeting of specific pathways. The aim of this study was to determine whether expression of glucose transporter-1 (GLUT-1) and p53 in pretreatment rectal cancer biopsies was predictive of tumor response to chemoradiotherapy. Immunohistochemical staining for GLUT-1 and p53 was performed on 69 pretreatment biopsies and compared to tumor response in the resected specimen as determined by the tumor regression grade (TRG) scoring system. GLUT-1 expression was significantly associated with reduced response to chemoradiotherapy and increasing GLUT expression correlated with poorer response (p=0.02). GLUT-1 negative tumors had a 70% probability of good response (TRG3/4) compared to a 31% probability of good response in GLUT-1 positive tumors. GLUT-1 may be a useful predictive marker of response to chemoradiotherapy in rectal cancer.-
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshFemale-
dc.subject.meshGlucose Transporter Type 1-
dc.subject.meshHumans-
dc.subject.meshImmunoenzyme Techniques-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPreoperative Care-
dc.subject.meshPrognosis-
dc.subject.meshRectal Neoplasms-
dc.subject.meshRetrospective Studies-
dc.subject.meshTreatment Outcome-
dc.subject.meshTumor Markers, Biological-
dc.subject.meshTumor Suppressor Protein p53-
dc.titleGLUT-1 expression and response to chemoradiotherapy in rectal cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland. sbrophy@rcsi.ieen
dc.identifier.journalInternational journal of cancer. Journal international du canceren
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.